CN1730029A - Method for preparing red sage formulation or buccal tablet for treating coronary disease - Google Patents
Method for preparing red sage formulation or buccal tablet for treating coronary disease Download PDFInfo
- Publication number
- CN1730029A CN1730029A CN 200510090061 CN200510090061A CN1730029A CN 1730029 A CN1730029 A CN 1730029A CN 200510090061 CN200510090061 CN 200510090061 CN 200510090061 A CN200510090061 A CN 200510090061A CN 1730029 A CN1730029 A CN 1730029A
- Authority
- CN
- China
- Prior art keywords
- heart disease
- red sage
- coronary heart
- powder
- buccal tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a salvia miltiorrhizae preparation for treating coronary disease, which is prepared from the following raw material (by weight ratio), salvia miltiorrhizae 440-520g, notoginseng 440-520g, rosewood oil 3.8-4.6ml.
Description
Technical field
The present invention relates to a kind of medicine that is used for the treatment of coronary heart disease.
Background technology
Coronary heart disease is the abbreviation of coronary atherosclerotic heart disease, coronary artery supply heart self-blood, and serious atherosis or spasm takes place in coronary artery, makes coronary stricture or obturation, is a kind of heart disease that causes myocardial ischemia, anoxia or infraction.Its main clinical manifestation is myocardial ischemia, anoxia and the angina pectoris, the arrhythmia that cause, and myocardial infarction can take place severe patient, makes myocardium large tracts of land necrosis, threat to life.The cardiovascular diseases has been involved the whole world as " first killer " of harm humans health, is the main disaster of many rich countries.By 1940, coronary heart disease became the underlying cause of death of the U.S. and some industrialized country.
According to 11 national data that World Health Organization (WHO) announces nineteen ninety, the coronary heart disease death rate was the highest with Northern Ireland in 30～69 years old.Although before the mortality rate of U.S.'s coronary heart disease was than 30 years, descended 40%, but still occupied first of U.S.'s cause of the death.The data of the U.S. that NCHS in 1988 announces death toll in 1987 and ordinal cause of death shows that heart disease accounts for 35% of total cause of the death, and wherein coronary heart disease death accounts for 24.1%, first of 10 causes of the death that rank forefront.Compared with developed countries, China still belongs to low country of coronary heart disease, but since the eighties, China's cardiovascular diseases's M ﹠ M is ascendant trend year by year.According to World Health Organization's report, in per 3 the dead persons in the whole world, just there is 1 people to die from cardiovascular disease, and most country that occurs in middle and low income.According to 1984, the coronary heart disease death rate: the city was 36.9/10 ten thousand, and the rural area is 15.6/10 ten thousand.1985～1989 years Monica schemes of Beijing's cardiopulmonary blood vessel center monitoring result shows that in 48 monitoring center by the WHO tissue, 35～64 years old coronary heart disease markization mortality rate of China only is higher than Japan, arranges second from the bottom.The males with coronary disease mortality rate is 49,/10 ten thousand, and the women is 27,/10 ten thousand, and the Finland higher with mortality rate (male 4,93/,100,000, and the women 63,/10 ten thousand) differs greatly.1986～nineteen ninety China to 10 groups of crowd's hypertension, coronary heart disease, stroke onset extremely the perspective study result of risk factor show, in 3819659 people/years of monitoring, 409 examples take place in acute myocardial infarction male altogether, the women is 200 examples, annual morbidity is respectively 10～26,/10 ten thousand, 8～13,/10 ten thousand; Mortality rate is respectively 4～11,/10 ten thousand and 2～5,/10 ten thousand.The coronary heart disease death number accounts for 4.47% (man) and 3.72 (woman) of total cause of the death.Had data to show in 96 years, it is about 1/3 that the cardiovascular and cerebrovascular disease death toll has accounted for total death toll, and coronary heart disease accounts for 15%.
The expert of World Health Organization (WHO) says: " unless strengthen community's crowd prevention and treatment energetically, otherwise, human spreading with this world's pestilence of uncontrollable cardiovascular diseases." in China, the preventing and treating cardiovascular disease of carrying out large-scale crowd is very urgent.
Show that after deliberation Chinese medicine has better curative effect to coronary heart disease, can reduce the side effect of Western medicine, reduce the relapse rate of disease, become one of Therapeutic Method that adopts clinically.By retrieval, GUANXIN DANSHEN DIWAN is the active drug of treatment coronary heart disease, has obtained curative effect preferably in clinical practice, is accepted by numerous doctors and patients deeply.
Coronary heart disease belongs to categories such as motherland's medical science thoracic obstruction, chest pain, angina pectoris, precordial pain with cold limbs.The traditional Chinese medical science thinks that its generation is relevant with inside and outside two aspect factors.Wherein exopathogenic factor is many because it is attacked by the cold and evil or surfeit delicious food; Endogenous cause of ill is many to be injured due to the five internal organs because seven emotions are too drastic, loses motive degradation, kidney qi day after the prime of life, spleen soil is strong, insufficiency of lung-QI, liver-yang are high partially, also is the pathogenetic endogenous cause of ill of coronary disease place.The stagnation of QI due to the above various reasons, blood stasis, stagnation of phlegm are pathological product, are again main paathogenic factors.
The main pathogenesis of coronary heart disease is a deficiency in origin and excess in superficiality.Deficiency in origin is based on the deficiency of vital energy, the deficiency of YIN; Mark is real to be seen so that the stagnation of QI, blood stasis, expectorant are turbid more.Insufficiency of heart-QI then gas can not to promote blood capable and blood is capable slow; Deficiency of spleen-QI can not fortune make Tianjin be expectorant with fixed attention; Deficiency of kidney-QI can not be agitated heart-yang, blockage of the cardiac vessels; Insufficiency of lung-QI, the pectoral qi weakness, fortune blood is unable, then blood stasis due to qi deficiency; Deficiency of liver-blood, asthenic fire are from prosperous, and refining liquid is expectorant; Deficiency of kidney yin can not nourish the moon of the five internal organs, and the heart-yin in-fighting stagnates the blood vessels stasis of blood.Zhang Tiezhong etc. think that the stagnation of QI, blood stasis, expectorant are turbid, make blood vessels obstructed and angina pectoris takes place.Yang Kaiqing etc. think expectorant stasis of blood resistance numbness heart arteries and veins, and QI-blood circulation is not smooth, and heart kidney loses QI and blood nourishings that make moist, and then heart deficiency of the kidney void further increases the weight of for a long time, forms excess caused by deficiency, because of the real vicious cycle that causes void.In treatment, Zhang Tiezhong etc. think that the angina pectoris pathogenesis is a deficiency in origin and excess in superficiality, thus control should the spleen invigorating QI invigorating, nourishing YIN for benefiting the kidney, blood circulation promoting and blood stasis dispelling, dehumidifying reduce phlegm.Height is washed wind and is thought controlling of coronary heart disease, says the doctrine of the mean most, avoid with attacking big benefit greatly, QI invigorating with invigorate blood circulation just rightly, not helping heresy to set upright, attacking that heresy do not hinder just is principle.Wang Xiaofang etc. think qi as the commander of blood, and desiring to invigorate blood circulation must first Xingqi gas, and therefore vital energy regualting and blood circulation-promoting, mutual causality of ascending and descending are answered in treatment.Yue Meizhong treatment coronary heart disease is emphasized " mansion that breast is clear sun ", " the cloudy sun of using of heart body ", thinks should reach logical medicine to clean up " YIN pathogen " with positive medicine by the treatment obstruction of qi in the chest and cardialgia.Ran Xuefeng diagnosis and treatment angina pectoris is advocated lead to afterwards earlier and is mended, the analgesic therapy that takes stopgap measures earlier, after the Gu void of effecting a permanent cure.Opinion cardiopathia such as Yang Kaiqing are controlled from the kidney opinion, utilization reinforcing kidney and strengthening resistance method, invigorating kidney, promoting blood circulation method, the kidney invigorating eliminating phlegm method, the kidney warming expelling phlegm method, the kidney invigorating qi-promoting method treatment coronary heart disease.
The traditional Chinese medical science is thought coronary heart disease is that function is deficient because worn with age, yin and yang qi and blood disorder, and the influence of seven emotions six climate exopathogens causes qi depression to blood stasis in addition, and hypofunction of YANG QI in chest is given birth in expectorant is turbid, makes blockage of the cardiac vessels and causes a disease.Mao Shi thinks that coronary heart disease is by deficiency of spleen-YANG and kidneyYANG, deficiency of heart-QI, and dysfunction of the spleen in warming is due to the turbid cohesion of expectorant.When Liu Shi thought insufficiency of lung-QI, the motive was unable, and blood fortune is not smooth, and the stasis of blood hinders that general rule is not pained.Lu Shi thinks angina pectoris mainly due to irritability stasis, stagnation of turbid phlegm in middle-JIAO, and the cold coagulation stasis is due to the heart arteries and veins stasis of blood hinders.Zhao Shi thinks that the beginning and end are closely related with the stasis of blood invariably.
Modern study shows: the greasy and surfeit flavour person is eaten in happiness usually, and the plasma lipoprotein amount is higher than the normal person; " A " type actor cause of coronary heart disease chance is " B " type actor twice in the seven emotions factor, and its main cause is that " A " type actor's blood viscosity and platelet aggregation increases; Hyperlipemia, hemodynamics, the impaired and microcirculation disturbance of the unusual cardiac function of hemorheology is again to cause qi depression to blood stasis, the pathophysiological basis of the turbid retardance of expectorant.
From lot of documents, Chinese herb decoction treatment angina pectoris is followed differential diagnosis in terms of eight principles and corresponding to determining the pathogenesis of ZANG-FU disease based on the differentiation of symptoms and signs more.In general, the traditional Chinese medical science is thought the sick position of this disease at the heart, and is relevant with spleen (stomach), kidney, liver many internal organs such as (gallbladders), presents the pathological characters of deficiency in origin and excess in superficiality.The deficiency in origin duty in gas, blood, yin, yang, mark is real to relate generally to the stagnation of QI, blood stasis, phlegm retention, cold coagulation, pathological product or factor such as burning hot.Deficiency in origin is marked actually based on blood stasis so that the deficiency of vital energy is the most outstanding again.Liu De is identical to carry out the research of dialectical rule to 92 routine spontaneous angina pectoriss and the anginal TCM Syndrome Type of 303 routine fatigues, find to have general character therebetween, dialectical in 395 routine patients is syndrome of deficiency of QI person 246 examples, account for 62.3%, blood stasis proposita 272 examples, account for 68.9%, can think that in view of the above the basic pathogenesis of angina pectoris is blood stasis due to qi deficiency, deficiency in origin and excess in superficiality.
At present, Chinese medicine preparation mainly contains FUFANG DANSHEN DIWAN, FUFANG DANSHEN PIAN, makes by Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum, has obtained good effect.Yet though above-mentioned three kinds of composition synergism are relatively good, its absorption is slower.
Summary of the invention
The object of the present invention is to provide a kind ofly, be used for uncomfortable in chest, chest pain, shortness of breath and palpitation due to the qi stagnation and blood stasis type coronary heart disease, have instant effect, effective advantage the medicative red sage formulation of coronary heart disease.
Red sage formulation provided by the invention is made by following raw material: Radix Salviae Miltiorrhizae 440-520 gram, Radix Notoginseng 440-520 gram, Lignum Dalbergiae Odoriferae oil 3.8-4.6ml.
Preferred mode is that described red sage formulation is made by following raw material: Radix Salviae Miltiorrhizae 480g, Radix Notoginseng 480g, Lignum Dalbergiae Odoriferae oil 4.2ml.
Described red sage formulation can be the dosage form on buccal tablet, granule, effervescent tablet, capsule and other all pharmaceuticss, the preferred port buccal tablet, and with respect to other dosage forms such as drop pill, buccal tablet uses convenient.
Also contain following adjuvant, cane sugar powder 170g, soluble starch 232g, citric acid 30g, protein sugar 40g, apple essence 3g, magnesium stearate 6g, and ginsenoside R in the used raw material of described buccal tablet
G1Gross weight content in this buccal tablet is not less than 1.13 ‰.
The present invention also provides a kind of preparation method of coronary heart disease buccal tablet, and this method comprises following process:
(1) Radix Salviae Miltiorrhizae is used the alcohol reflux secondary, each 60-80 minute, merge extractive liquid, filtered, filtrate recycling ethanol, and be condensed into clear paste, standby.
(2) Radix Notoginseng powder is broken into coarse powder, with alcohol reflux twice, each 1.1-1.9 hour, merge extractive liquid, filters filtrate recycling ethanol, and be condensed into clear paste, it is an amount of to add kieselguhr, mixing, drying under reduced pressure is ground into fine powder, adds the alcohol reflux secondary, each 0.7-1.3 hour, merge extractive liquid, filtered, filtrate recycling ethanol is condensed into clear paste, and is standby.
(3) with in (1) with (2) in the clear paste that makes at last merge spray drying.
(4) dried cream powder that obtains in (3) is added cane sugar powder, soluble starch, citric acid, protein sugar, mixing is used alcohol granulation, is pressed through sieve, 50～60 ℃ of dryings, granulate adds apple essence, magnesium stearate, sprays into Lignum Dalbergiae Odoriferae oil, airtight, be pressed into 1000, the bag film-coat.
In the side, Radix Notoginseng: sweet in the mouth, little hardship, warm in nature.Return liver, stomach, the heart, lung, large intestine channel.The function blood that looses, analgesic therapy (Compendium of Material Medica); All puerperal, menstrual period, traumatic injury, carbuncle, all blood stasis be broken (" beautiful Chinese catalpa medicine is separated ") all; Can be in its blood stasis of blood systemization (" book on Chinese herbal medicine be looked for the truth ").Because of its blood that can loose, and can be except that the main cause of pain due to blood stasis warp; Because of it can analgesic therapy, and can treat the primary symptom of pain due to blood stasis warp.So be the monarch drug in the side.
Radix Salviae Miltiorrhizae: bitter in the mouth, cold nature.GUIXIN, pericardium, Liver Channel, the function promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, the removing heat from blood eliminating carbuncle, relieving restlessness is calmed the nerves.Cure mainly: menoxenia, amenorrhea dysmenorrhea, the stagnant stomachache of the stasis of blood in puerperal etc." can break stagnated blood, mend snow newly " (Compendium of Material Medica).
Lignum Dalbergiae Odoriferae: acrid in the mouth, warm in nature.Return liver, spleen channel.Cure mainly: hemorrhage, costa sternales pain is fallen and is decreased stasis of blood pain, vomiting stomachache." treat folding and hinder incised wound, hemostasis analgesic therapy, detumescence and promoting granulation " (Compendium of Material Medica).
All medicines cooperate, pass through reasonable compatibility, play blood circulation promoting and blood stasis dispelling altogether, the effect of regulating QI to relieve pain is used for uncomfortable in chest, chest pain, shortness of breath and palpitation due to the qi stagnation and blood stasis type coronary heart disease, particularly Lignum Dalbergiae Odoriferae oil is an ethereal oil, it is very fast to be absorbed by the body, and is used for patients with coronary heart disease, rapid-action, can eliminate symptoms such as uncomfortable in chest, chest pain, shortness of breath and palpitation fast, alleviate ailing.
Coronary heart disease buccal tablet of the present invention is Film coated tablets, removes to show pale brown color behind the coating to sepia; Select correctives and excipient by science, can correct the bitterness of Radix Salviae Miltiorrhizae, Radix Notoginseng and the suffering flavor of Lignum Dalbergiae Odoriferae, make its gas delicate fragrance, sweet and sour, be fit to suck, with respect to other agent shape advantage easy to carry, as to need not to use water delivery service is arranged then as buccal tablet, also overcome the oral liquid need with the inconvenience that suction pipe brings, be particularly suitable for the coronary heart disease patient and carry use.
The preparation method of coronary heart disease buccal tablet of the present invention adopts special extraction process, can guarantee that medicinal ingredient is fully extracted, to guarantee its therapeutic effect.
The specific embodiment
Below in conjunction with specific embodiment pharmaceutical preparation of treatment coronary heart disease of the present invention and preparation method thereof is described further.
Embodiment 1
Present embodiment is the coronary heart disease buccal tablet, is formed by following feedstock production, and every weight is 0.6 gram, and every contains ginsenoside R
G1(C
42H
72O
14) must not be less than 6.8mg: Radix Salviae Miltiorrhizae 480g, Radix Notoginseng 480g, Lignum Dalbergiae Odoriferae oil 4.2ml.
Its preparation method is: Radix Salviae Miltiorrhizae alcohol reflux secondary, and each 70 minutes, merge extractive liquid, filtered, filtrate recycling ethanol, and be concentrated into the clear paste that relative secret agreement is 1.10 (60 ℃), standby.Radix Notoginseng powder is broken into coarse powder, with 70% alcohol reflux twice, and each 1.5 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃ of surveys), it is an amount of to add kieselguhr, mixing, 80 ℃ of drying under reduced pressure, be ground into fine powder, add the alcohol reflux secondary, each 1 hour, merge extractive liquid, filters filtrate recycling ethanol, be concentrated into the clear paste that relative density is about 1.10 (60 ℃), merge spray drying with the Radix Salviae Miltiorrhizae clear paste.Dried cream powder adds the about 170g of cane sugar powder, the about 232g of soluble starch, the about 30g of citric acid, the about 40g of protein sugar, mixing is used 95% alcohol granulation, is pressed through 16 mesh sieves, 50～60 ℃ of dryings, granulate adds the about 3g of apple essence, magnesium stearate 6g, sprays into Lignum Dalbergiae Odoriferae oil, airtight, be pressed into 1000, the bag film-coat, promptly.
This product is a Film coated tablets, removes to show pale brown color behind the coating to sepia; Gas delicate fragrance, sweet and sour.
Function cures mainly: blood circulation promoting and blood stasis dispelling, and regulate the flow of vital energy and go up pain.Be used for uncomfortable in chest, chest pain, shortness of breath and palpitation due to the qi stagnation and blood stasis type coronary heart disease.
Usage and dosage: buccal.An a slice, 3 times on the one.
Embodiment 2
Present embodiment is the GUANXIN DANSHEN KELI agent, is formed by following feedstock production, and every bag of weight is 8 grams:
Principal agent: Radix Salviae Miltiorrhizae 442g, Radix Notoginseng 518g, Lignum Dalbergiae Odoriferae oil 3.9ml.
Its preparation method is: Radix Salviae Miltiorrhizae alcohol reflux secondary, and each 70 minutes, merge extractive liquid, filtered, filtrate recycling ethanol, and be concentrated into the clear paste that relative secret agreement is 1.10 (60 ℃), standby.Radix Notoginseng powder is broken into coarse powder, with 70% alcohol reflux twice, and each 1.5 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃ of surveys), it is an amount of to add kieselguhr, mixing, 80 ℃ of drying under reduced pressure, be ground into fine powder, add the alcohol reflux secondary, each 1 hour, merge extractive liquid, filters filtrate recycling ethanol, be concentrated into the clear paste that relative density is about 1.10 (60 ℃), merge spray drying with the Radix Salviae Miltiorrhizae clear paste.Dried cream powder adds right amount of auxiliary materials, makes soft material with 95% ethanol, sieves, dry, granulate, sprays into Lignum Dalbergiae Odoriferae oil, makes granule, pack, and every bag heavy 8 gram, every bag contains ginsenoside R
G1(C
42H
72O
14) must not be less than 6.8mg.
Function cures mainly: blood circulation promoting and blood stasis dispelling, and regulate the flow of vital energy and go up pain.Be used for uncomfortable in chest, chest pain, shortness of breath and palpitation due to the qi stagnation and blood stasis type coronary heart disease.
Usage and dosage: warm boiled water, every day three times, each 1 bag.
Embodiment 3
Present embodiment is a GUANXIN DANSHEN JIAONANG, is formed by following feedstock production, and every weight is 0.6 gram, and every contains ginsenoside R
G1(C
42H
72O
14) must not be less than 6.8mg:
Principal agent: Radix Salviae Miltiorrhizae 520g, Radix Notoginseng 440g, Lignum Dalbergiae Odoriferae oil 4.6ml.
Its preparation method is: Radix Salviae Miltiorrhizae alcohol reflux secondary, and each 70 minutes, merge extractive liquid, filtered, filtrate recycling ethanol, and be concentrated into the clear paste that relative secret agreement is 1.10 (60 ℃), standby.Radix Notoginseng powder is broken into coarse powder, with 70% alcohol reflux twice, and each 1.5 hours, merge extractive liquid,, filter, filtrate recycling ethanol, and be concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃ of surveys), it is an amount of to add kieselguhr, mixing, 80 ℃ of drying under reduced pressure, be ground into fine powder, add the alcohol reflux secondary, each 1 hour, merge extractive liquid, filters filtrate recycling ethanol, be concentrated into the clear paste that relative density is about 1.10 (60 ℃), merge spray drying with the Radix Salviae Miltiorrhizae clear paste.Right amount of auxiliary materials and dried medicated powder are mixed and made into granule and incapsulate after drying, every Chinese medicine weight is 0.6 gram, wherein contains ginsenoside R
G1(C
42H
72O
14) must not be less than 6.8mg.
Function cures mainly: blood circulation promoting and blood stasis dispelling, and regulate the flow of vital energy and go up pain.Be used for uncomfortable in chest, chest pain, shortness of breath and palpitation due to the qi stagnation and blood stasis type coronary heart disease.
Usage and dosage: buccal.One time one, 3 times on the one.
Claims (5)
1, a kind of red sage formulation for the treatment of coronary heart disease is made by following raw material: Radix Salviae Miltiorrhizae 440-520 gram, Radix Notoginseng 440-520 gram, Lignum Dalbergiae Odoriferae oil 3.8-4.6ml.
2, the red sage formulation of treatment coronary heart disease as claimed in claim 1 is characterized in that: described red sage formulation is made by following raw material: Radix Salviae Miltiorrhizae 480g, Radix Notoginseng 480g, Lignum Dalbergiae Odoriferae oil 4.2ml.
3, the red sage formulation of treatment coronary heart disease as claimed in claim 1 or 2 is characterized in that: described red sage formulation is the dosage form on buccal tablet or granule, effervescent tablet, capsule and other all pharmaceuticss.
4, the red sage formulation of treatment coronary heart disease as claimed in claim 3, it is characterized in that: also contain following adjuvant in the used raw material of described buccal tablet, cane sugar powder 170g, soluble starch 232g, citric acid 30g, protein sugar 40g, apple essence 3g, magnesium stearate 6g, and the gross weight content of ginsenoside Rg1 in this buccal tablet is not less than 1.13 ‰.
5, the preparation method of the described buccal tablet of a kind of claim 4, this method comprises following process:
(1) Radix Salviae Miltiorrhizae is used the alcohol reflux secondary, each 60-80 minute, merge extractive liquid, filtered, filtrate recycling ethanol, and be condensed into clear paste, standby.
(2) Radix Notoginseng powder is broken into coarse powder, with alcohol reflux twice, each 1.1-1.9 hour, merge extractive liquid, filters filtrate recycling ethanol, and be condensed into clear paste, it is an amount of to add kieselguhr, mixing, drying under reduced pressure is ground into fine powder, adds the alcohol reflux secondary, each 0.7-1.3 hour, merge extractive liquid, filtered, filtrate recycling ethanol is condensed into clear paste, and is standby.
(3) with in (1) with (2) in the clear paste that makes at last merge spray drying.
(4) dried cream powder that obtains in (3) is added cane sugar powder, soluble starch, citric acid, protein sugar, mixing is used alcohol granulation, is pressed through sieve, 50～60 ℃ of dryings, granulate adds apple essence, magnesium stearate, sprays into Lignum Dalbergiae Odoriferae oil, airtight, be pressed into 1000, the bag film-coat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100900612A CN100393330C (en) | 2005-08-11 | 2005-08-11 | Method for preparing red sage formulation or buccal tablet for treating coronary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100900612A CN100393330C (en) | 2005-08-11 | 2005-08-11 | Method for preparing red sage formulation or buccal tablet for treating coronary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1730029A true CN1730029A (en) | 2006-02-08 |
| CN100393330C CN100393330C (en) | 2008-06-11 |
Family
ID=35962475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100900612A Expired - Fee Related CN100393330C (en) | 2005-08-11 | 2005-08-11 | Method for preparing red sage formulation or buccal tablet for treating coronary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100393330C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784504A (en) * | 2014-01-24 | 2014-05-14 | 中发实业集团业锐药业有限公司 | Traditional Chinese medicinal composition and preparation method thereof |
| CN108743663A (en) * | 2018-06-01 | 2018-11-06 | 广西昌弘制药有限公司 | The preparation method of coronary heart disease thin membrane coated tablet |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381135C (en) * | 2003-12-31 | 2008-04-16 | 天津天士力制药股份有限公司 | Application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance |
-
2005
- 2005-08-11 CN CNB2005100900612A patent/CN100393330C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784504A (en) * | 2014-01-24 | 2014-05-14 | 中发实业集团业锐药业有限公司 | Traditional Chinese medicinal composition and preparation method thereof |
| CN108743663A (en) * | 2018-06-01 | 2018-11-06 | 广西昌弘制药有限公司 | The preparation method of coronary heart disease thin membrane coated tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100393330C (en) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285309B (en) | Rhodiola rosea compound composition for treating peptic ulcer | |
| CN103285310B (en) | Use of rhodiola rosea compound composition in preparing medicine for curing gastric ulcer | |
| CN1899379A (en) | External plaster for treating child cold diarrhea and preparing method | |
| CN103272170B (en) | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer | |
| CN1634250A (en) | Compound injectio of Chinese angelica and astragalus root and its preparing process | |
| CN104013919A (en) | Traditional Chinese medicine for treating angina pectoris | |
| CN100393330C (en) | Method for preparing red sage formulation or buccal tablet for treating coronary disease | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| CN1279944C (en) | Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN104857121A (en) | Drug combination for curing hyperlipidemia and application thereof | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN105214035A (en) | One treats peptic ulcer tablet and preparation method thereof | |
| CN1111420C (en) | Exterior-applied medicine for treating lumbar intervertebral disk protrusion | |
| CN1053111C (en) | Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing | |
| CN101028482A (en) | Stomach-clearing pill | |
| CN1943755A (en) | A Chinese traditional medicinal composition for treatment of hypertension and its preparation method | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1241632C (en) | Chinese patent medicine for treating cardiac function failure and its preparation method | |
| CN1247237C (en) | Medicinal composition for treating coronary disease and its preparation and application | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN105596893A (en) | Traditional Chinese medicine composition for treating hyperlipidaemia and preparation method | |
| CN105250951A (en) | Preparing method for medicine for treating peptic ulcer | |
| CN1853711A (en) | Xinmaikangzhong Chinese medicinal composition and preparation thereof | |
| CN1292782C (en) | Medication of tonifying the kidney and strengthening the spleen, and producing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080611 Termination date: 20100811 |